| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454415 | Lung Cancer | 2017 | 7 Pages |
Abstract
This study reviewed the prevalence of uncommon EGFR mutations and their sensitivity to EGFR-TKIs. Favorable responses were observed in patients with G719X and compound L858R mutations, indicating that they may benefit from EGFR-TKIs as a first-line therapy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, Yue-Li Sun, Hong-Hong Yan, Ming-Ying Zheng, Xiao-Yan Bai, Zhen Wang, Jian Su, Zhi-Hong Chen, Xu-Chao Zhang, Zhong-Yi Dong, Si-Pei Wu, Ben-Yuan Jiang, Hua-Jun Chen, Bin-Chao Wang, Chong-Rui Xu, Qing Zhou, Yi-Long Wu,